ChromoReport Fall 2019 - Performance of Multi-Country vs. Single Country Studies

Tufts CSDD START II Research Report
Globalization has an obvious impact on organizational structure of clinical operations teams. Do centralized groups outperform non-dedicated groups? A comprehensive study conducted by Tufts Center for the Study of Drug Development (CSDD), Start-up Time And Readiness Tracking (START) II, concluded that there was no conclusive evidence that centralizing the function of site identification through to activation achieved significant improvements in terms of cycle time reductions. Irrespective of organizational structure both groups face similar challenges and see the same opportunities for improvement.

But what do the industry metrics have to say about cycle time performance of multi-country vs. single country studies? And economies of scale in clinical trials?